source · text/csv
source_d9ddeefdcf2c4589
sha256 a544ed05fc27e5b4370df5b01ee6afa95aeb988986afe741001be4c9f4951b9f
by researka:v2 · 2026-06-19 00:45:24.790388+04:00
study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness "Comparative Effectiveness of CagriSegma , Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta‐Analysis of Randomized Clinical Trials",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Efficacy and safety of oral semaglutide in older patients with type 2 diabetes: a retrospective observational study (the OTARU-SEMA study),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary "Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary "Safety and Efficacy of Semaglutide in Patients With Chronic Kidney Disease, With or Without Type 2 Diabetes: A Systematic Review and Meta‐Analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis *,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary "Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson’s disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary Gastrointestinal safety evaluation of semaglutide for the treatment of type 2 diabetes mellitus: A meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level "Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level "**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation "**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation "**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Studenski 2011,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Cesari 2009,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Perera 2006,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation ADA 2024,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation WHO 2000,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Bohannon 1997,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Cruz-Jentoft 2019,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Tinetti 1988,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Tancredi 2015,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation Ioannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "060fa963-9582-4658-ad87-91a057301d4f",
"researka_submission_id": "807814a9-fc08-449b-8a72-18e47e815d0d",
"sidecar_name": "evidence_table.csv",
"sidecar_url": "https://api.researka.org/publications/060fa963-9582-4658-ad87-91a057301d4f/sidecars/evidence_table.csv"
}